Blockchain Registration Transaction Record

Silo Pharma Secures Canadian Patent for PTSD Treatment SPC-15

Silo Pharma receives Canadian patent allowance for SPC-15, an intranasal PTSD treatment. This milestone advances its pipeline and global IP strategy. Learn more about the impact.

The Canadian patent allowance for SPC-15 is a crucial step for Silo Pharma, as it strengthens the company's intellectual property position in a key market and validates the potential of its lead candidate. For patients suffering from PTSD, this news offers hope for a novel intranasal treatment that could address an unmet medical need. The streamlined 505(b)(2) pathway may lead to faster approval and lower development costs, potentially accelerating access to this innovative therapy. For investors, this milestone enhances Silo's commercial prospects and could positively impact the company's valuation.